Scaling basic toxicokinetic parameters from rat to man

Environmental Health Perspectives

Volumn 104, Issue 4, 1996, Pages 400-407

  Bachmann, Kenneth ^a   Pardoe, David ^b   White, Donald ^a,b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

Author keywords

Half life; Humans; Pharmacokinetics; Rats; Scaling; Toxicokinetics; Volume of distribution

Indexed keywords

XENOBIOTIC AGENT;

ARTICLE; BODY SURFACE; BODY WEIGHT; COMPARATIVE STUDY; HALF LIFE TIME; HUMAN; INTOXICATION; MATHEMATICAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE; TOXICOKINETICS; TOXICOLOGY;

EID: 0029941301     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.96104400     Document Type: Article

References (148)

1. Boxenbaum H, Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 245:R768-R775 (1983).
2. Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 15:1071-1121 (1984).
3. Gerlowski L, Jain R. Physiologically based pharmacokinetic modeling:principles and applications. J Pharm Sci 72:1103-1126 (1983).
4. Sawada Y, Harashima H, Hanano M, Sugiyama Y, Iga T. Prediction of the plasma concentration time courses of various drugs in humans based on data from rats. J Pharmacobio-Dyn 8:757-766 (1985).
5. Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201-227 (1982).
6. Fan A, Howd R, Davis B. Risk assessment of environmental chemicals. Annual Reviews of Pharmacol Toxicol 35:341-368 (1995).
7. Travis C, White R. Interspecies scaling of toxicity data. Risk Anal 8:119-125 (1988).
8. Sidhu K. Basis for body weight exponent (0.75) as a scaling factor in energy metabolism and risk assessment. J Appl Toxicol 12:309-310 (1992).
9. Travis C, White R, Ward, R. Interspecies extrapolation of pharmacokinetics. J Theor Biol 142:285-304 (1990).
10. Boxenbaum H, Fertig J. Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. Eur J Drug Metab Pharmacokinet 9:177-183 (1984).
11. Andersen ME, Krishnan K, Conolly R, McClellan R. Biologically based modeling in toxicology research. Arch Toxicol 15:217-227 (1992).
12. Krewski D, Withey J, Ku L, Andersen ME. Applications of physiologic pharmacokinetic modeling in carcinogenic risk assessment. Environ Health Perspect 102(suppl 11):37-50 (1994).
13. Brazzell R, Park T, Wooldridge C, McCue B, Barker R, Couch R, Yark B. Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors. Drug Metab Dispos 18: 435-440 (1990).
14. Wientjes MG, Levy G. Nonlinear pharmacokinetics of aspirin in rats. J Pharmacol Exp Ther 245:809-815 (1988).
15. Benet L, Williams R. Design and optimization of dosage regimens. In: The pharmacological basis of therapeutics, 8th ed (Goodman Gilman A, Rall T, Nies A, Taylor P, eds). New York:Pergamon Press, 1990;1650-1735.
16. Patel B, Boudinot D, Schinazi R, Galb J, Chu C. Comparative pharmacokinetics and interspecies scaling of 3′-azido-3′-deoxythmidine (AZT) in several mammalian species. J Pharmacobio-Dyn 13:206-211 (1990).
17. Efthymiopoulos C, Battaglia R, Strolin MB. Animal pharmacokinetics and interspecies scaling of FCE 22101, a penem antibiotic. J Antimicrob Chemother 27:517-526 (1991).
18. Rose S, Jenner P, Marsder C. Peripheral pharmacokinetics handling and metabolism of L-dopa in the rat:the effect of route of administration and cardidopa pretreatment. J Pharm Pharmacol 43:325-330 (1991).
19. Robertson DR, Wood ND, Everest H, Monks K, Waller DG, Renwick A, George CF. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol 28:61-69 (1989).
20. Owens S, Hardwick W, Blackall D. Phencyclidine pharmacokinetic scaling among species. J Pharmacol Exp Ther 242:96-101 (1987).
21. Belanger P, Lalande M, Dore F, Labricque G. Time-dependent variations in the organ extraction ratios of acetaminophen in rat. J Pharmacokinet Biopharm 15:133-141 (1987).
22. McGovern J, Williams M, Stewart J. Interspecies comparison of acivicin pharmacokinetics. Drug Metab Dispos 16:18-22 (1988).
23. Fujioka Y, Mizuno N, Morita E, Motozono H, Takahashi K, Yamanaka Y, Shinkuma D. Effect of age on the gastrointestinal absorption of acyclovir in rats. J Pharm Pharmacol 43:465-469 (1991).
24. Hori R, Ite Y, Shima T, Invi K, Aoki S, Okumura K, Tanigawara Y. Total body and hepatic clearance in rats of recombinant tissue type plasminogen activator expressed in mouse C127 and Chinese hamster ovary cells. Drug Metab Dispos 20:541-546 (1992).
25. Wyss P, Moor J, Bickel M. Single-dose kinetics of tissue distribution, excretion and metabolism of amiodarone in rats. J Pharmacol Exp Ther 254:502-504 (1990).
26. Miyake K, Fukuchi H, Kitaura T, Kimura M, Kimura Y. Pharmacokinetic analysis of amitriptyline and demethylated metabolite in serum and brain of rats after acute and chronic oral administration of amitriptyline. J Pharmacobio-Dyn 15:157-166 (1992).
27. Sawada Y, Hanano M, Sugiyama Y, Iga T. Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetcs in rats. J Pharmacokinet Biopharm 13:477-492 (1985).
28. Torres-Molina F, Aristorena J. Garcia-Carbonell, Granero L, Chese-Jimenez J, PlaDelfina J, Peris-Ribeno J. Influence of permanent cannulation of the jugular vein on pharmacokinetics of amoxycillin and antipyrine in the rat. Pharm Res 9:1587-1591 (1992).
29. Fielding R, Smith P, Wang L, Porter J, Guo L. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCB, and a conventional formulation to rats. Antimicrob Agents Chemother 35:1208-1213 (1991).
30. Ben-Zvi Z, Hreash F, Kaplanski J. Disposition of hexobarbitone and antipyrine in DOCA-hypertensive rats. J Pharm Pharmacol 43:349-352 (1991).
31. Shobha J, Raghuram T. Antipyrine kinetics in undernourished diabetics. Eur J Clin Pharmacol 41:359-361 (1991).
32. Belpaire F, DeSmet F, Vyackier L, Vermeulen A. Rosseel M, Bogaert M, Chauvelot-Moachan L. Effect of aging on the pharmacokinetics of atenolol, metoprolol and propranolol in the rat. J Pharmacol Exp Ther 254:116-122 (1990).
33. Mandema J, Heijligers-Feijen C, Tukker E, DeBoer A, Danhof M. Modeling of the effect site equilibration kinetics and pharmacodynamics of racemic baclofen and its enantiomers using quantitative EEG effect measures. J Pharmacol Exp Ther 261:88-94 (1992).
34. Wuis E, Dirks M, Termond E, Vree T, Vanderkleijn E. Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. Eur J Clin Pharmacol 37:181-184 (1989).
35. Kurihara A, Naganuma H, Hisaoka M, Tokiwn H, Kawaharia G. Prediction of human pharmacokinetics of panipenem-betamipron, a new carbopenem from animal data. Antimicrob Agents Chemother 36:1810-1815 (1992).
36. Bonati M, Latini R, Tognoni G, Young J, Garattini S. Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat and mouse. Drug Metab Rev 15:1355-1383 (1984-85).
37. Turner P, Renton K. The interaction between carbamazepine and erythromycin. Can J Physiol Pharmacol 67:582-586 (1989).
38. Garcia-Carborell M, Granero L, Torres-Molina F, Aristorena J, Peris-Ribera E. Nonlinear pharmacokinetics of cefadroxil in the rat. Drug Metab Dispos 21:215-217 (1993).
39. Sawada Y, Hanano M, Sugivama Y, Iga T. Prediction of the disposition of b-lactam antibiotics in humans from pharmacokinetic parameters in animals. J Pharmacokinet Biopharm 12:241-261. (1984).
40. Matsushita H, Suzuki H, Sugiyama Y, Sawada Y, Iga T, Hanano M, Kawaguchi Y. Prediction of the pharmacokinetics of cefodizime and cefotetan in humans from their pharmacokinetic parameters in animals. J PharmacobioDyn 13:602-611 (1990).
41. Korting H, Schafer-Korting M, Maass L, Klesel N, Mutschler E. Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers. Antimicrob Agents Chemother 31:1822-1825 (1987).
42. Isert D, Kiesel N, Limbert M, Markus A, Seibert G, Schrinner E. Pharmacokinetics of cefpirone administered intravenously or intramuscularly to rats and dogs. J Antimicrob Chemother 29:31-37 (1992).
43. Kavi J, Andrews J, Ashby J, Hillman G, Wise R. Pharmacokinetics and tissue penetration of cefpirome, a new cephalosporin. J Antimicrob Chemother 22:911-916 (1988).
44. Mordenti J. Pharmacokinetic scale-up:accurate prediction of human pharmacokinetic profiles from animal data. J Pharm Sci 74:1098 (1995).
45. Nakashima E, Matshushita R, Takeaki M, Nakanishi T, Ichimura F. Comparative pharmacokinetics of cefoperazone and cephradine in untreated streptozotocin diabetic rats. Drug Metab Dispos 20:730-735 (1992).
46. Pettijohn F, Potter P, Siever R. Relation between binding to plasma protein, apparent volume of distribution and rate constants of disposition and elimination for chlorpromazine in three species. J Pharm Pharmacol 24:818-819 (1972).
47. Gomita Y, Eto K, Furuno K, Araki Y. Effects of exposure to standard-and-nicotine-reduced cigarette smoke on pharmacokinetics of theophylline and cimetidine in rats. J Pharm Sci 81:1132-1135 (1992).
48. Litterst C, Magin R. Alterations in plasma pharmacokinetics of cisplatin in tumor-bearing rats. Cancer Chemother Pharmacol 22:1-4 (1988).
49. Woodnutt G, Kernutt I, Mizen L, Mizen L. Pharmacokinetics and distribution of ticarcillin-clauvlanic acid (Timentin) in experimental animals. Antimicrob Agents Chemother 31:1826-1830 (1987).
50. Boni J, Barr W, Martin B. Cocaine inhalation in the rat:pharmacokinetics and cardiovascular response. J Pharmacol Exp Ther 257:307-315 (1991).
51. Boxenbaum H. Interspecies scaling, allometry, physiological time and the ground plan of pharmacokinetics. J Pharmacokin Biopharm 10:206-213 (1982).
52. Sangalli L, Bartolotti, Jiritano L, Bonati M. Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats and humans. Drug Metab Dispos 16:749-753 (1988).
53. Igari Y, Sugiyama Y, Sawada Y, Iga T, Hanano M. In vitro and in vivo assessment of hepatic and extra-hepatic metabolism of diazepam in the rat. J Pharm Sci 73:825-828 (1984).
54. Lin J, Hooke K, Yeh K, Duggan D. Dose-dependent pharmacokinetics of difllunisal in rats:dual effects of protein binding and metabolism. J Pharmacol Exp Ther 235:402-406 (1985).
55. Harrison L, Gibaldi M. Pharmacokinetics of digoxin in the rat. Drug Metab Dispos 4:88-93 (1976).
56. Tsunekawa Y, Hasegawa T, Nadai M, Takagi K, Nabeshima T. Interspecies differences and scaling for the pharmacokinetics of xanthine derivatives. J Pharm Pharmacol 44:594-599 (1992).
57. Kinoshita H, Ohishi N, Kato M, Tokura S, Okazaki A. Pharmacokinetics and distribution of recombinant erythropoietin in rats. Arzneim-Forsch 42:174-178 (1992).
58. Salmonson T, Danielson B, Wikstrom B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmacol 29:709-713 (1990).
59. DaSilva V, McLean A. Effect of two different types of malnutrition on the rate of elimination of ethanol in rats. Biocheml Pharmacol 37:4235-4238 (1988).
60. Bachmann K, Jahn D, Yang C, Schwartz J. Ethosuximide disposition kinetics in rats. Xenobiotica 18:373-380 (1988).
61. Chien D, Sandri R, Tang-Liu D. Systemic pharmacokinetics of acitretin, etretinate, isotretinoin and acetylenic retinoids in guinea pigs and obese rars. Drug Metab Dispos 20:211-217 (1992).
62. Larsen F, Jakobsen P, Larsen C. Norgaard A, Kragballe K, Nielsen-Kudsk F. Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. Pharmacol Toxicol 61:85-88 (1987).
63. Lin JH, Los L, Ulm E, Duggan P. Urinary excretion kinetics of famotidine in rats. Drug Metab Dispos 15:212-215 (1987).
64. Adusumalli V, Yang J, Wong K, Kucharczyk N, Sofia R. Felbamate Pharmacokinetics in the rat, rabbit and dog. Drug Metab Dispos 19:1116-1125 (1991).
65. Graves N, Ludden T, Holmes G, et al. Pharmacokinetics of felbamate, a novel antiepileptic drug:Application of mixed-effect modeling to clinical trials. Pharmacotherapy 9:372-376 (1989).
66. Hug C Jr, Murphy M. Tissue redistribution of fentanyl and termination of its effects in rats. Anesthesiology 55:369-375 (1981).
67. Caccia S, Cappi M, Fracasso C, Garattini S. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology 100:509-514 (1990).
68. Berry B, Jamali F. Enantiomeric interaction of flurbiprofen in the rat. J Pharm Sci 78:632-634 (1989).
69. Kean W, Antal E, Grace E, Cauvier H, Rischke J, Buchanan W. The pharmacokinetics of flurbiprofen in younger and elderly patients with rheumatoid arthritis. J Clin Pharmacol 32:41-48 (1992).
70. Engineer M, Bodley G Sr, Newman R, W-Ho D. Effects of cisplatin-induced nephrotoxicity on gentamicin pharmacokinetics in rats. Drug Metab Dispos 15:329-334 (1987).
71. Shah A, Jung D. Dose-dependent pharmacokinetics of ibuprofen in the rat. Drug Metab Dispos 15:151-154 (1987).
72. Sawada Y, Hanano M, Sugivama Y, Harashima H, Iga T. Prediction of the volumes of distribution of basic drugs in human based on data from animals. J Pharmacokinet Biopharm 12:587-596 (1984).
73. Ogiso T, Ito Y, Iwaki M, Atago H. A pharmacokinetic model for the percutaneous absorption of indomethacin and the prediction of drug disposition kinetics. J Pharm Sci 78:319-323. (1989).
74. Zeruesenay D, Siegmund W, Zschiesche M, Franke G, Walter R, Bleyer H. Pharmacokinetic interactions between isoniazid and theophylline in rats. J Pharm Pharmacol 44:893-897 (1992).
75. Chien D, Sandri R, Tang-Liu D. Systemic pharmacokinetics of acitretin, etretinate, isotretinoin and acetylenic retinoids in guinea pigs and obese rats. Drug Metab Dispos 20:211-217 (1992).
76. Remmel R, Amoh K, Abdel-Monem M. The disposition and pharmacokinetics of ketoconazole in the rat. Drug Metab Dispos 15:735-739 (1987).
77. Foster R, Jamali F. Stereoselective pharmacokinetics of ketoprofen in the rat. Drug Metab Dispos 16:623-4526. (1988).
78. Mroszczak E, Lee F, Combs D, Sarquist F, Huang B, Wu A, Tokes L, Maddox M, Cho D. Ketorolac, tromethamine absorption, distribution, metabolism, excretion and pharmacokinetics in animals and humans. Drug Metab Dispos 15:618-626 (1987).
79. Fruncillo R, Digregorio G. Pharmacokinetics of pentobarbital, quinidine, lidocain and theophylline in the thermally injured rat. J Pharm Sci 73:1117-1121 (1984).
80. Bredberg U, Paalzow L. Pharmacokinetics of methysergide and its metabolite methylergometrine in the rat. Drug Metab Dispos 18:338-343 (1990).
81. Bredberg U, Eyjolfsdottir, Paalow L, Tfelt-Hansen V, Tfelt-Hanson V. Pharmacokinetics of methysergide and its metabolite methylergometrine in man. Eur J Clin Pharmacol 30:75-77 (1986).
82. Ling G, Umans J, Inturrisio C. Radio immunoassay and pharmacokinetics in the rat. J Pharmacol Exp Ther 217:147-151 (1981).
83. Bakke O, Segura J. The absorption and elimination of metoclopramide in three animal species. J Pharm Pharmacol 28:32-39 (1976).
84. Aarons L, Mandema J, Danhof M. A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat. J of Pharmacokin Biopharm 19:485-496 (1991).
85. Bhargava H, Villar V. Pharmacodynamics and pharmacokinetics of intravenously administered morphine in spontaneously hypertensive and normotensive Wistar-Kyoto rats. J Pharmacol Exp Ther 261:290-296 (1992).
86. Higuchi S, Shiobana Y. Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator in various species. Xenobiotica 10:447-454 (1980).
87. Kveremater G, Taylor L, DeBethizv J, Vessel E. Pharmacokinetics of nicotine and 12 metabolites in the rat. Application of a new radiometric high performance liquid chromatographic assay. Drug Metab Dispos 16:125-129 (1988).
88. Okezaki E, Terasaki T, Nakamura M, Nagata O, Kara H, Tsuji A. Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. Drug Metab Dispos 16:865-874 (1988).
89. Lode H, Hoffken G, Prinzing C, Glarzel P, Wiley R, Olschewski P, Sievers B, Reimnitz D, Borner K, Koeppe P. Comparative pharmacokinetics of new quinolones. Drugs 34(suppl 1):21-25 (1987).
90. Ichimura F, Yokoyawa K, Yamana T, Tsuji A, Mizukami Y. Physiologic pharmacokinetic model for pentazocin, I. tissue distribution and elimination in the rat. Int J Pharm 15:321-333 (1983).
91. Said S, Foda A. Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man. Arzneim-Forsch 39:790-792 (1989).
92. Nicols A, D'Ambrosio R, Pyszczynski N, Jusko W. Pharmacokinetics and pharmacodynamics of prednisolone in obese rats. J Pharmacol Exp Ther 250:963-970 (1989).
93. Huang M, Jusko W. Nonlinear pharmacokinetics and interconversion of prednisolone and prednisone in rats. J Pharmacokinet Biopharm 18:401-421 (1990).
94. Basseches P, DiGregorio G. Pharmacokinetics of procainamide in rats with extra-hepatic biliary obstruction. J Pharm Sci 71:1256-1259 (1982).
95. Puigdemont A, Guitart R, DeMora F, Arboix M. Prediction of the disposition of propafenone in humans and dogs from pharmacokinetic parameters in other animal species. J Pharm Sci 80:1106-1109 (1991).
96. Evans G, Nies A, Shand D. The disposition of propranolol III. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J Pharmacol Exp Ther 186:114-122 (1973).
97. Mihaly G, Date N, VeeNendaal J, Newman K, Smallwood R. Decreased hepatic elimination of pyrimethamine during malaria infection. Biochemical Pharmacol 36:2827-2829 (1987).
98. Harashima H, Sawada, Sugiyama Y, Iga T, Hanano M. Analysis of non-linear tissue distribution of quinidine in rats by physiologically based pharmacokinetics. J Pharmacokinet Biopharm 13:425-440 (1985).
99. Yih T, Van Rossum, J. Pharmacokinetics of some homologous series of barbituates in the intact rat and in the isolated perfused rat liver. J Pharmacol Exp Ther 203:184-202 (1977).
100. Breimer D. Clinical pharmacokinetics of hypnotics. Clin Pharmacokinet 2:93-109 (1977).
101. Tremaine L, Welch W, Ronfeld R. Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog. Drug Metab Dispos 17:542-550 (1989).
102. DeVane C. Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 53:2(suppl) 13-19 (1992).
103. Kaul S, Ritschel W. Quantitative structure-pharmacokinetic relationship of a series of sulfonamides in the rat. Eur J Drug Metab Pharmacokinet 15:211-217 (1990).
104. Sabater J, Domenech J, Obach R. Pharmacokinetic study of tolmetin in the rat. Arzneim-Forsch 42:950-953 (1992).
105. Tu Y, Allen L, Fiorica V, Albers D. Pharmacokinetics of trimethoprim in the rat. J Pharm Sci 78:556-560 (1989).
106. Engineer M, Ho D, Bodey G. Comparison of vancomycin disposition in rats with normal and abnormal renal function. Antimicrob Agents Chemother 20:718-722 (1981).
107. Galinsky R, Levy G. Dose and time-dependent elimination of acetaminophen in rats: pharmacokinetic implications of cosubstrate depletion. J Pharmacol Exp Ther 219:14-20 (1981).
108. Brigden D, Whiteman P. The clinical pharmacology of acyclovir and its prodrugs. Scand J Infect Dis 47:(suppl)33-39 (1985).
109. Tanswell P, Heinzel G, Greischel A, Krause J. Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver. J Pharmacol Exp Ther 255:318-324 (1990).
110. Roberts R, Grice J, Wood L, Petroff V, McGuffie C. Cimetidine impairs the elimination of theophylline and antipyrine. Gastroenterology 81:19-21 (1981).
111. Adedoyin A, Aarons L, Houston J. Dose-dependent pharmacokinetics of cimetidine in the rat. Xenobiotica 17:595-604 (1987).
112. Bjorkman S, Stanski D, Verotta D, Harashima H. Comparative tissue concentration profiles of fentanyl and alfentanil in humans predicted from tissue/blood partitition data obtained in rats. Anesthesiology. 72:865-873 (1990).
113. Taylor I, Ioannides C, Sacra P, Turner J, Parke D. Effect of deuteration of imipramine on its pharmacokinetic properties in the rat. Biochem Pharmacol 32:641-647 (1983).
114. Guissou P, Cuisinaud G, Legheand J, Sassard J. Chronopharmacokinetics of indomethacin in rats. Arzneim-Forsch 37:1034-1037 (1987).
115. Vermeulen A, Belpaire F, DeSmet F, Vercruysse I, Boggaert M. Aging and the pharmacokinetics and metabolism of metoprolol enantiomers in the rat. J Gerontol Biol Sci 48:B108-B114 (1993).
116. Miyamoto Y, Ozaki M, Yamamoto H. Effects of adrenalectomy on pharmacokinetics and antinociceptive activity of morphine in rats. Jpn J Pharmacol 46:379-386 (1988).
117. Hussey E, Donn K, Daniel M, Hall S, Harker A, Evans G. Interspecies scaling and pharmacokinetic parameters of 3TC in humans. J Clin Pharmacol 34:975-977 (1994).
118. Tanaka H, Kaneko T. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor in the rat. Single and multiple dosing studies. Drug Metab Dispos 19:200-204 (1991).
119. Drug facts and comparisons. St. Louis, MO:Facts and Comparisons, Inc.,1995.
120. Merck and Company. Clinical investigator's confidential informational brochure. MK-0476 summary of information. Rahway, NJ, 1994.
121. Baggot J. Application of interspecies scaling to the bispyridinium oxime HI-6. Am J Vet Res 55:689-691 (1994).
122. Hollinger B, Pastoor T. Case management and plasma half-life in a case of brodifacoum poisoning. Arch Intern Med 153:1925-1928 (1993).
123. Bachmann K, Sullivan T. Dispositional and Pharmacodynamic characteristics of brodifacoum in warfarin-sensitive rats. Pharmacology 27:281-288 (1983).
124. Shah J, Mason W. A dose-ranging study of the pharmacokinetics of codeine phosphate following intravenous administration to rats. J Pharm Sci 80:229-231 (1991).
125. Sanders S, Buchi K, Goddard M, Lang J, Tolman K. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob Agents Chemother 35:1029-1034 (1991).
126. Ibrahim S, Boudinot F. Pharmacokinetics and 2′, 3′-dideoxycytidine after high-dose administration to rats. J Pharm Sci 80:36-38 (1991).
127. Ibrahim S, Boudinot F. Pharmacokinetics and 2′, 3′-dideoxycytidine in rats: application to interspecies scale-up. J Pharm Pharmacol 41:829-834 (1988).
128. Borga O, Andersson K, Edholm L, Fagerstrom P, Lunell E, Persson C. Enprofylline genetics in healthy subjects after single doses. Clin Pharmacol Ther 34:799-804 (1983).
129. Bachmann K, Chu C, Greear V. In vivo evidence that ethosuximide is a cytochrome P450IIIA substrate. Pharmacology 45: 121-128 (1992).
130. Bachmann K, Schwartz J, Sullivan T, Jauregui L. Single sample estimate of ethosuximide clearance. Int J Clin Pharmacol Ther Toxicol 24:546-550 (1986).
131. Groeseneken D, Veulemans H, Masschelein R, Van Vlem E. Comparative urinary excretion of ethoxyacetic acid in man and rat after single low doses of ethylene glycol monoethyl ether. Toxicol Lett 41:57-68 (1988).
132. Jezequel S. Fluconazole:Interspecies scaling and allometric relationships of pharmacokinetic properties. J Pharm Pharmacol 46:196-199 (1993).
133. Vollmer K, von Hodenberg A, Kölle E. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneim-Forsch 36:830-838 (1986).
134. Van der Graaff M, Vermeulen N, Breimer D. Disposition of hexobarbital:15 years of an intriguing model substrate. Drug Metab Rev 19:109-164 (1988).
135. Wood A, Goodwin G, DeSouza R, Green A. The pharmacokinetic profile of lithium in rat and mouse. An important factor in psychopharmacological investigation of the drug. Neuropharmacol 25:1285-1288 (1986).
136. Dickinson R, Baker P, Franklin M, Hooper W. Facile hydrolysis of meberine in vitro and in vivo:Negligible circulating concentrations of the drug after oral administration. J Pharm Sci 80:952-957 (1991).
137. Farris F, Dedrick R, Allen P, Smith C. Physiological model for the pharmacokinetics of methylmercury in the growing rat. Toxicol Appl Pharmacol 119:74-90 (1993).
138. Smith J, Allen P, Turner M, Most B, Fisher H, Hall L. The kinetics of intravenously administered methylmercury in man. Toxicol Appl Pharmacol 128:251-256 (1994).
139. Malviya V, Young J, Boike G, Gove N, Deppe G. Pharmacokinetics of mitomycin-C in plasma and tumor tissue of cervical cancer patients and in selected tissues of female rats. Gynecol Oncol 25:160-170 (1986).
140. Yuan J, Goehl T, Hong L, Clark J, Murrill E, Moore R. Toxicokinetics of oxazepam in rats and mice. J Pharm Sci 83:1373-1379 (1994).
141. Bernard E, Donnely H, Maher M, Armstrong D. Use of a new bioassay to study pentamidine pharmacokinetics. J Infect Dis 152:750-754 (1985).
142. Trenk D, Jähnchen E. Effect of serum protein binding on pharmacokinetics and anticoagulant activity of phenprocoumon in rats. J Pharmacokinect Biopharm 8:177-191 (1980).
143. Haustein K, Huller G. Pharmacokinetics of phenprocoumon. Int J Clin Pharmacol Ther 32:192-197 (1994).
144. Somani S, Khalique A. Pharmacokinetics and pharmacodynamics of physostigmine in the rat after intravenous administration. Drug Metab Dispos 15:627-633 (1987).
145. Johansson M, Nordberg A. Pharmacokinetic studies of cholinesterase inhibitors. Acta Neural Scand 149:522-525 (1993).
146. Gascón A, Calvo B, Hernandez R, Dominguez-Gil A, Pedraz J. Interspecies scaling of cimetidine-theophylline pharmacokinetic interaction: interspecies scaling in pharmacokinetic interactions. Pharm Res 11:945-950 (1994).
147. Manitpisitkul P, Chiou W. Intravenous verapamil kinetics in rats. Marked arteriovenous concentration difference and comparison with humans. Biopharm Drug Dispos 14:555-566 (1993).
148. Takada K, Levy G. Comparative pharmacokinetics of coumarin anticoagulants XLIV. Dose dependent pharmacokinetics of warfarin in rats. J Pharm Sci 69:9-14 (1980).